Phase 2 N=40 Sumatriptan as Treatment for Post-traumatic Headache
Post-traumatic Headache
Primary: Change in Headache Relief — 23 percentage of headaches resolved — p=.079
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=104 A Study Comparing Eribulin Mesylate and Ixabepilone in Causing or Exacerbating Neuropathy in Participants With Advanced Breast Cancer
Breast Cancer
Primary: Percentage of Participants With Treatment-Emergent Neuropathy Adverse Events (AEs) — 33.3; 50.0 Percentage of participants — p==0.0941
Phase 2 N=13 Study of Axitinib in Patients With Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas
Neurofibromatosis Type 2 · Vestibular Schwannomas
Primary: Expression Levels of p-S6 Based Immunohistochemistry (Histoscore) — 90 score
Phase 2 N=134 MK-7625A Versus Meropenem in Pediatric Participants With Complicated Urinary Tract Infection (cUTI) (MK-7625A-034)
Complicated Urinary Tract Infection · Pyelonephritis
Primary: Number of Participants With ≥1 Adverse Events (AEs) — 59; 20 Participants
Phase 2 N=101 Response-Based Therapy Assessed By PET Scan in Treating Patients With Bulky Stage I and Stage II Classical Hodgkin Lymphoma
Lymphoma
Primary: Progression-free Survival at 36 Months — 93.1; 89.7 percentage of participants — p=0.9669
Phase 2 N=26 Treatment of Chronic Delta Hepatitis With Lonafarnib, Ritonavir and Lambda Interferon
Liver Disease · Hepatitis D
Primary: Number of Participants With Decline of Hepatitis D Virus (HDV) RNA Viral Titer of >2 Logs — 18 Participants
Phase 2 N=481 A Trial to Evaluate OPC 67683 in Participants With Pulmonary Sputum Culture-positive, Multidrug-resistant Tuberculosis (TB)
Tuberculosis, Pulmonary · Tuberculosis, Multidrug Resistant · Extensively Drug-Resistant Tuberculosis
Primary: Percentage of Participants Who Achieved Sputum Culture Conversion (SCC) Using the Mycobacteria Growth Indicator Tube (MGIT) System — 45.4; 41.9; 29.6 percentage of…
Phase 2 N=143 Study of Efficacy and Safety of DV890 in Patients With COVID-19 Pneumonia
COVID-19 Pneumonia, Impaired Respiratory Function
Primary: APACHE II Severity of Disease Score on Day 15 or on the Day of Discharge (Whichever is Earlier) — 8.7; 8.6 Score on a scale — p=0.467
Phase 2 N=29 TPIV200/huFR-1 (A Multi-Epitope Anti-Folate Receptor Vaccine) Plus Anti-PD-L1 MEDI4736 (Durvalumab) in Patients With Platinum Resistant Ovarian Cancer
Ovarian Cancer
Primary: Overall Response Rate — 1; 6; 4; 18 Participants
Phase 2 N=17 Combined Tretinoin and Arsenic Trioxide for Patients With Newly Diagnosed Acute Promyelocytic Leukemia Followed by Risk-Adapted Postremission Therapy
Acute Promyelocytic Leukemia
Primary: To Determine the Rate of Molecular Remission
Phase 2 N=75 Low-Dose or High-Dose Lenalidomide in Treating Younger Patients With Recurrent, Refractory, or Progressive Pilocytic Astrocytoma or Optic Pathway Glioma
Neurofibromatosis Type 1 · Recurrent Childhood Pilocytic Astrocytoma · Recurrent Childhood Visual Pathway Glioma
Primary: Number of Patients Who Demonstrate Complete or Partial Response — 4; 4 Participants
Phase 2 N=7 Mechanisms of Refractory Hypertension (Reserpine)
Refractory Hypertension
Primary: Change Ambulatory Systolic Blood Pressure — -29.3 mmHg
Phase 2 N=122 Pharmacokinetic Study to Evaluate Double-Dose Levonorgestrel Emergency Contraception in Combination With Efavirenz-Based Antiretroviral Therapy or Rifampicin-Containing Anti-Tuberculosis Therapy
HIV Infections · Tuberculosis
Primary: LNG Area Under the Concentration-time Curve (AUC0-8h) Calculated Based on Intensive LNG PK Samples Obtained From Individual Participants — 52.13; 102.13; 80.50; 124.39…
Phase 2 N=46 Pembro/Carbo/Taxol in Endometrial Cancer
Endometrial Cancer · Endometrial Adenocarcinoma
Primary: Objective Response Rates (ORR) — 74.4 percentage of participants
Phase 2 N=125 A Study Evaluating the Safety and Efficacy of Brexucabtagene Autoleucel (KTE-X19) in Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ZUMA-3)
Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia
Primary: Phase 1: Percentage of Participants Experiencing Dose Limiting Toxicities (DLTs) — 0 percentage of participants